fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

MHLW (Japan) approves Uptravi tablets for pediatric pulmonary arterial hypertension – Nippon Shinyaku

Written by | 28 Jan 2025 | Cardiology

Nippon Shinyaku Co., Ltd. announced that it has obtained approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for Uptravi tablets 0.2 mg and 0.4 mg for the additional indication of pediatric pulmonary arterial hypertension (PAH), as well as for a new drug application for Uptravi  tablets for pediatric 0.05 mg. PAH is a disease with a poor prognosis characterized by abnormally high blood pressure in the pulmonary artery. It is classified into idiopathic PAH, heritable PAH and PAH associated with various diseases such as connective tissue disease and congenital heart disease. Because the disease pathology of PAH is similar between pediatric and adult patients, combination therapy of prostacyclin pathway drug, endothelin receptor antagonist and phosphodiesterase-5 inhibitor, is also recommended for pediatric PAH patients. However, treatment options for pediatric PAH are limited in Japan. Particularly, in the case of prostacyclin pathway drug, only an injectable formulation requiring continuous intravenous infusion is available. Therefore, there has been an unmet need for oral formulations of prostacyclin pathway drug.

Uptravi is an oral prostacyclin receptor (IP receptor) agonist with high selectivity for the IP receptor among prostacyclin pathway drugs. Uptravi is believed to reduce pulmonary arterial pressure by binding to the IP receptors on vascular smooth muscle cells and increasing cAMP production, thereby leading to vasodilation and inhibition of vascular smooth muscle proliferation.on Uptravi therapy, as uninterrupted treatment is considered key for individuals with PAH. Uptravi tablets were first approved by the FDA in 2015 to delay disease progression and reduce the risk of hospitalization for PAH.

The optimal dose of Uptrav for each patient is determined by dose titration. The new 0.05 mg tablet allows for finer dosing for pediatric patients, but some patients may need to take a larger number of tablets at one time. To support patents and healthcare professionals who take and dispense the drug,the company e developed a new pill case especially for the pediatric formulation.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.